Findings Of Cancer Research Articles

A Smartphone based Automated Primary Screening of Oral Cancer based on Deep Learning

In low- and middle-income countries, oral cancer is becoming more common. One factor delaying the discovery of oral cancer in rural areas is a lack of resources. To stop the disease from spreading, it is essential to quickly obtain information about any cancers. Therefore, it is essential to carry out early identification before it spreads. Primary screening is maintained in this study. Furthermore, deep neural network-based automated methods were used to produce complex patterns to address the challenging issue of assessing oral cancer infection. The goal of this work is to develop an Android application that uses a deep neural network to categorize oral photos into four groups: erythroplakia, leukoplakia, ulcer, and normal mouth. Convolutional neural networks and K-fold validation processes are used in this study’s methodology to create a customized Deep Oral Augmented Model (DOAM). Data augmentation techniques including shearing, scaling, rotation, and flipping are used to pre-process the images. A convolutional neural network is then used to extract features from the images Optimal configurations of max pooling layers, dropout, and activation functions have resulted in the attainment of maximum accuracies. By using the ”ELU” activation function in conjunction with RMSProp as the optimizer, the model achieves 96% validation accuracy, 96% precision, 96% F1 score, and 68% testing accuracy. The model is then deployed in TensorFlow Lite using an Android application.

Crown-like Biodegradable Lipids Enable Lung-Selective mRNA Delivery and Dual-Modal Tumor Imaging In Vivo.

Systemic mRNA delivery to specific cell types remains a great challenge. We herein report a new class of crown-like biodegradable ionizable lipids (CBILs) for predictable lung-selective mRNA delivery by leveraging the metal coordination chemistry. Each CBIL contains an impressive crown-like amino core that coordinates with various metal ions such as Zn2+ and further regulates the in vivo organ-targeting behavior of lipid nanoparticles (LNPs). The representative CBIL (Zn-9C-SCC-10)-formulated LNPs could exclusively deliver mRNA to the lung after systemic administration. Notably, following intravenous administration of 0.2 mg kg-1 Cre mRNA, Zn-9C-SCC-10 LNPs enabled the highly efficient gene editing of all lung epithelial and endothelial cells up to 43 and 61%, respectively, outperforming the current state-of-the-art LNPs in lung epithelial cell delivery. Moreover, compared to DLin-MC3-DMA LNPs with the addition of cationic lipid (DOTAP), our approach yielded a 44.6-fold enhancement in pulmonary mRNA expression and significantly improved biosafety in vivo. Taking advantage of paramagnetic gadolinium ion, Gd-12C-SCC-10 LNPs allowed the potent mRNA delivery to cancer cells and successfully illuminated lung tumors by magnetic and bioluminescent dual-mode imaging, facilitating the early discovery and diagnosis of lung cancer. This work will open a new avenue to rationally design predictable LNPs, as well as address the major challenges of mRNA delivery to specific cells in the lung tissues for treating a wide variety of diseases.

Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies

BackgroundThe global landscape of public health faces significant challenges attributed to the prevalence of cancer and the emergence of treatment resistance. This study addresses these challenges by focusing on Cyclin-dependent Kinase 2 (CDK2) and employing a systematic computational approach for the discovery of novel cancer therapeutics.ResultsInitial ligand-based pharmacophore modelling, utilizing a training set of five reported CDK2 inhibitors, yielded a robust model characterized by Aro|Hyd| and |Acc|Don| features. Screening this validated model against the ZINC database identified 1881 hits, which were further subjected to molecular docking studies. The top 10 compounds (Z1–Z10) selected from the docking studies underwent Pharmacokinetic parameters Absorption, Distribution, Metabolism, Excretion and Toxicity profiling, Density Functional Theory (DFT) studies and the top two went for 100ns molecular dynamics (MD) simulations by comparing them with the standard Roscovitine. Compounds Z1 and Z2 emerged as the most promising, with docking scores of − 8.05 kcal/mol and − 8.02 kcal/mol, respectively. DFT analysis of the top 10 compounds revealed minimal variations in highest occupied molecular orbital–lowest unoccupied molecular orbital energy gaps, indicating consistent electronic stability and reactivity across the candidates. MD simulations of Z1 and Z2 confirmed their stable interactions with CDK2, with root mean square deviation (RMSD) values ranging from 1.4 to 2.5 Å for Z1 and 1.5 to 2.4 Å for Z2.ConclusionThe current research identified compounds Z1 and Z2, which demonstrated significant potential as potent CDK2 inhibitors for cancer therapy, providing valuable insights into the development of more effective CDK2 inhibitors and addressing the critical need for innovative therapeutic strategies in cancer treatment.Graphical abstract

Metabolic interactions of host-gut microbiota: New possibilities for the precise diagnosis and therapeutic discovery of gastrointestinal cancer in the future-a review.

Gastrointestinal (GI) cancer continues to pose a significant global health challenge. Recent advances in our understanding of the complex relationship between the host and gut microbiota have shed light on the critical role of metabolic interactions in the pathogenesis and progression of GI cancer. In this study, we examined how microbiota interact with the host to influence signalling pathways that impact the formation of GI tumours. Additionally, we investigated the potential therapeutic approach of manipulating GI microbiota for use in clinical settings. Revealing the complex molecular exchanges between the host and gut microbiota facilitates a deeper understanding of the underlying mechanisms that drive cancer development. Metabolic interactions hold promise for the identification of microbial signatures or metabolic pathways associated with specific stages of cancer. Hence, this study provides potential strategies for the diagnosis, treatment and management of GI cancers to improve patient outcomes.

Analysis of Determinants of Underutilization of VIA Test on Early Discovery of Cervical Cancer in Cimahi City

Analysis of Determinants of Underutilization of VIA Test on Early Discovery of Cervical Cancer in Cimahi City

Single hollow-core microstructure fiber biosensor for pancreatic cancer diagnosis in terahertz regime

Abstract Pancreatic cancer is a kind of malignant tumor that is difficult to detect in its early stages, developing rapidly and with a 5-year survival rate of only 5% to 10%. Therefore early diagnosis and discovery of pancreatic cancer are very important for the successful treatment of the disease. Here, we report a single hollow-core microstructural fiber (SHC-MSF) biosensor based on a ZEONEX substrate, which has been optimized for the early detection of pancreatic cancer biomarkers. The proposed SHC-MSF biosensor adopts a single-aperture structure to increase the contact range with assay analytes to improve the detection sensitivity. Its biosensing performance was numerically analyzed using a finite element method with a perfect matching layer. Numerical results demonstrated that the proposed MSF-biosensor presented ultra-high sensitivity (bilirubin: 105.55%, glucose: 105.34%, creatinine: 105.67%) and negligible confinement loss (bilirubin: 5.52×10-14 cm-1, glucose: 1.65×10-14 cm-1, creatinine: 5.57×10-14 cm-1) in the range of 0.3~2.0 THz. Moreover, the SHC-MSF biosensor could selectively detect and distinguish cancer markers of different concentrations in the blood to achieve a more accurate diagnosis of pancreatic cancer. Finally, fabrication tolerance analysis of the proposed MSF-biosensor is provided to ensure the feasibility of rapid preparation.

Discovery of Breast Cancer and Autism Causes Method of Combining Multiple Researches to Determine Non-Infectious Disease Causes

Discovery of Breast Cancer and Autism Causes Method of Combining Multiple Researches to Determine Non-Infectious Disease Causes

Discovery of mTOR Receptor Modulators Targeting Breast Cancer by Hybrid of Virtual Screening and Molecular Docking Approach

This research paper presents a comprehensive approach integrating virtual screening and molecular docking to identify potential therapeutic candidates. Pharmacophore-based virtual screening was employed to assess the structural similarities of compounds to a reference molecule, revealing promising candidates with high similarity scores. Subsequently, molecular docking studies were conducted to predict the binding affinities of these compounds to the target receptor, 4DRH. CHEMBL3775006 emerged as a lead candidate, demonstrating both structural resemblance and strong binding affinity to the target protein. ADME studies highlighted its pharmacokinetic properties, while toxicity prediction studies provided insights into potential adverse effects. Overall, this study underscores the utility of virtual screening and molecular docking in identifying novel drug candidates with therapeutic potential.

Unintentional discovery of a second cancer amidst laryngeal carcinoma surgery: case report of two patients

Unintentional discovery of a second cancer amidst laryngeal carcinoma surgery: case report of two patients

FATORES DE RISCO ASSOCIADOS AO DESENVOLVIMENTO DA DEPRESSÃO EM IDOSOS/AS ONCOLÓGICOS: Uma revisão integrativa da literatura

FATORES DE RISCO ASSOCIADOS AO DESENVOLVIMENTO DA DEPRESSÃO EM IDOSOS/AS ONCOLÓGICOS: Uma revisão integrativa da literatura

Abstract LB429: Discovery and identification of a novel cancer associated fibroblast target using Oxford Biotherapeutics (OBTs) OGAP discovery platform

Abstract Cancer Associated Fibroblasts (CAFs) are a major component of the tumor stromal microenvironment and have been indicated in promoting tumor growth as well as inhibiting tumor suppression mechanisms. One of the challenges in this field has been a lack of molecules that target CAFs specifically and can interfere with the CAF function. Here we describe a novel target discovered using OBTs proprietary OGAP platform, that appears to be specific for CAFs in a variety of tumor tissues. Interestingly this target appears to be minimally expressed in normal tissue fibroblasts by in situ hybridization RNA analysis but is highly upregulated in solid tissue stroma fibroblasts of colon, breast and pancreatic cancer tissues. The OGAP Discovery Platform utilizes a mass spectrometry approach to identify membrane targets on the surface of tumor cells as well as tumor microenvironment associated cells. This suggests that this novel target is expressed on the membrane of the CAFs making it a unique target for drug intervention. The identification of such a novel target is both exciting and a wonderful validation of OBTs OGAP Discovery Platform. Citation Format: Jeremy Sarnecky, Joseph Lewis, Jason Allen, Daniel Davies, Matthew Metzger, Ben Thomas, Christian Rohlff, Belinda Cairns. Discovery and identification of a novel cancer associated fibroblast target using Oxford Biotherapeutics (OBTs) OGAP discovery platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB429.

Comparative Study of Breast Cancer in Women Under 40 Compared to Older Women: The Experience of the Mohammed VI Center

Context: Breast cancer in young women is relatively rare worldwide, with patients under the age of 35 accounting for only 2% to 25% of all women diagnosed with this cancer. The objective of this study is to describe the epidemiological, clinical and histological profile of breast cancer in patients under 40 years of age. Methods: This is a comparative study between young and older patients at the Mohammed VI Center for Cancer Treatments. This study covered various aspects, including sociodemographic data and family history of cancer, gyneco-obstetrics, and circumstances of discovery of breast cancer, histopathological characteristics and molecular classification of breast cancer. Results: Among the 305 patients treated, 64 were aged 40 or younger, or 20.98% of the total. Breast cancer in our younger patients did not appear to differ significantly from that in older women, both in terms of sociodemographic factors and histopathological and molecular characteristics. The average age at first pregnancy was 23.85 years and the average parity was 1.58 children. 37.5% of young women were nulliparous. Among multiparous women, 95% breastfed their children. The average age of menarche was 13.34 years in young patients compared to 13.30 years in older patients (p = 0.85). Among the 6 postmenopausal patients (9.3% young women), the average age of onset of menopause was 39.17 years. 59.4% of young women used oral contraceptives, compared to 60.2% of older women. A family history of breast cancer was noted in 21.9% of young patients. The circumstances of discovery of breast cancer, most cases in both groups were identified by self-palpation or during a screening mammogram. The most common tumors were stage T2, involving lymph node invasion, and high-grade SBR II and III in 73.7% and 22.8% of cases, respectively. These were mainly invasive ductal carcinomas expressing hormonal receptors (ER and RP). About 30% were HER2+. No cases of bilateral cancer were observed in younger patients. Conclusion: Breast cancer in young women is a significant problem in our study population and its incidence is increasing worldwide. The absence of a systematic screening program before the age of 40 may explain the aggressive behavior of tumors in this age group.

β-Glucuronidase-triggered reaction for fluorometric and colorimetric dual-mode assay based on the in situ formation of silicon nanoparticles

Backgroundβ-Glucuronidase (GUS) is considered as a promising biomarker for primary cancer. Thus, the reliable detection of GUS has great practical significance in the discovery and diagnosis of cancer. Compared with traditional organic probes, silicon nanoparticles (Si NPs) have emerged as robust optical nanomaterials due to their facile preparation, superior photobleaching resistance and excellent biocompatibility. However, most nanomaterials-based methods only output a single signal which is easily influenced by external factors in complex systems. Hence, developing nanomaterial-based multi-signal optical assays for highly sensitive GUS determination is still urgently desired. ResultsIn this study, we developed a simple and efficient one-step method for the in situ preparation of yellow color and yellow-green fluorescent Si NPs. This was achieved by combining 3-[2-(2-aminoethylamino) ethylamino] propyl-trimethoxysilane with p-aminophenol (AP) in an aqueous solution. The obtained Si NPs showed yellow-green fluorescence at 535 nm when excited at 380 nm, while also exhibiting an absorption peak at a wavelength of 490 nm. Taking inspiration from the easy synthesis step regulated by AP, which is generated through the hydrolysis of 4-aminophenyl β-D-glucuronide catalyzed by GUS, we constructed a direct fluorometric and colorimetric dual-mode method to measure GUS activity. The developed fluorometric and colorimetric sensing platform showed high sensitivity and accuracy with detection limits for GUS determination as low as 0.0093 and 0.081 U/L, respectively. SignificanceThis study provides a facile dual-mode fluorometric and colorimetric approach for determination of GUS activity based on novel Si NPs for the first time. This designed sensing approach was successfully employed for the quantification of GUS in human serum samples and screening of GUS inhibitors, indicating the feasibility and potential applications in clinical cancer diagnosis and anti-cancer drug discovery.

Switching photocurrent polarity and mimicking enzyme functions of MIL-53(Fe)@hemin for homogeneous dual-modal ultrasensitive detection of PTP1B

Protein tyrosine phosphatase 1B (PTP1B) as a regulatory enzyme is an important target for the early diagnosis and drug discovery of diabetes, obesity, and cancer. Herein, a homogeneous dual-modal biosensor integrating photoelectrochemical and colorimetric (PEC-CL) strategies was developed in light of the switching photocurrent polarity and mimicking enzyme functions of MIL-53(Fe)@hemin for the sensitive detection of PTP1B activity. Magnetic Fe3O4@Au NPs were synthesized for more sufficient homogeneous biorecognition, and modified with the phosphorylated peptides (p-Peptide), and sequentially connected with MIL-53(Fe)@hemin by the specific coordination of phosphate groups with Fe(III). After PTP1B-mediated specific recognition and dephosphorylation, the separated MIL-53(Fe)@hemin were quickly collected via magnetic separation for further PEC and CL assay. MIL-53(Fe)@hemin not only switched the photocurrent polarity of SnS2 NFs from anode to cathode, but also exhibited excellent peroxidase-like activity for oxidizing 3,3′,5,5′-tetramethylbenzidine (TMB) in the presence of H2O2. As a signal amplifier, MIL-53(Fe) acted as a nanocarrier to load abundant PEC signal switching factor of hemin, and synergistically enhanced its enzyme-mimic property. Consequently, ultrasensitive PEC biosensing (with linear response range of 0.1 pg mL−1 to 3000 ng mL−1 and detection limit of 0.074 pg mL−1) assisted by visual CL strategy (with linear response range of 10 pg mL−1 to 3000 ng mL−1 and detection limit of 0.24 pg mL−1) for PTP1B activity assay were achieved, which not only provided high sensitivity, but also possessed portability, perceptual intuition and reliability.

Discovery of Endometrial Cancer After Removal of An Intrauterine Device Encrusted in the Myometrium

In our article, we report the case of a patient with metastatic endometrial cancer whose risk factor was an intrauterine device worn for over ten years.

From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.

Prostate cancer is the most common cancer in men worldwide and has a high mortality rate. The complex and heterogeneous development of prostate cancer has become a core obstacle in the treatment of prostate cancer. Simultaneously, the issues of overtreatment in early-stage diagnosis, oligometastasis and dormant tumor recognition, as well as personalized drug utilization, are also specific concerns that require attention in the clinical management of prostate cancer. Some typical genetic mutations have been proved to be associated with prostate cancer's initiation and progression. However, single-omic studies usually are not able to explain the causal relationship between molecular alterations and clinical phenotypes. Exploration from a systems genetics perspective is also lacking in this field, that is, the impact of gene network, the environmental factors, and even lifestyle behaviors on disease progression. At the meantime, current trend emphasizes the utilization of artificial intelligence (AI) and machine learning techniques to process extensive multidimensional data, including multi-omics. These technologies unveil the potential patterns, correlations, and insights related to diseases, thereby aiding the interpretable clinical decision making and applications, namely intelligent medicine. Therefore, there is a pressing need to integrate multidimensional data for identification of molecular subtypes, prediction of cancer progression and aggressiveness, along with perosonalized treatment performing. In this review, we systematically elaborated the landscape from molecular mechanism discovery of prostate cancer to clinical translational applications. We discussed the molecular profiles and clinical manifestations of prostate cancer heterogeneity, the identification of different states of prostate cancer, as well as corresponding precision medicine practices. Taking multi-omics fusion, systems genetics, and intelligence medicine as the main perspectives, the current research results and knowledge-driven research path of prostate cancer were summarized.

Diosbulbin C, a novel active ingredient in Dioscorea bulbifera L. extract, inhibits lung cancer cell proliferation by inducing G0/G1 phase cell cycle arrest

BackgroundDespite the critical progress of non-small cell lung cancer (NSCLC) therapeutic approaches, the clinical outcomes remain considerably poor. The requirement of developing novel therapeutic interventions is still urgent. In this study, we showed for the first time that diosbulbin C, a natural diterpene lactone component extracted from traditional Chinese medicine Dioscorea bulbifera L., possesses high anticancer activity in NSCLC.MethodsA549 and NCI-H1299 cells were used. The inhibitory effects of the diosbulbin C on NSCLC cell proliferation were evaluated using cytotoxicity, clone formation, EdU assay, and flow cytometry. Network pharmacology methods were used to explore the targets through which the diosbulbin C inhibited NSCLC cell proliferation. Molecular docking, qRT-PCR, and western blotting were used to validate the molecular targets and regulated molecules of diosbulbin C in NSCLC.ResultsDiosbulbin C treatment in NSCLC cells results in a remarkable reduction in cell proliferation and induces significant G0/G1 phase cell cycle arrest. AKT1, DHFR, and TYMS were identified as the potential targets of diosbulbin C. Diosbulbin C may inhibit NSCLC cell proliferation by downregulating the expression/activation of AKT, DHFR, and TYMS. In addition, diosbulbin C was predicted to exhibit high drug-likeness properties with good water solubility and intestinal absorption, highlighting its potential value in the discovery and development of anti-lung cancer drugs.ConclusionsDiosbulbin C induces cell cycle arrest and inhibits the proliferation of NSCLC cells, possibly by downregulating the expression/activation of AKT, DHFR, and TYMS.

Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome

Epidemiological studies suggest that individuals with neurodevelopmental disorders (NDDs) are more prone to develop certain types of cancer. Notably, however, the case statistics can be impacted by late discovery of cancer in individuals afflicted with NDDs, such as intellectual disorders, autism, and schizophrenia, which may bias the numbers. As to NDD-associated mutations, in most cases, they are germline while cancer mutations are sporadic, emerging during life. However, somatic mosaicism can spur NDDs, and cancer-related mutations can be germline. NDDs and cancer share proteins, pathways, and mutations. Here we ask (i) exactly which features they share, and (ii) how, despite their commonalities, they differ in clinical outcomes. To tackle these questions, we employed a statistical framework followed by network analysis. Our thorough exploration of the mutations, reconstructed disease-specific networks, pathways, and transcriptome levels and profiles of autism spectrum disorder (ASD) and cancers, point to signaling strength as the key factor: strong signaling promotes cell proliferation in cancer, and weaker (moderate) signaling impacts differentiation in ASD. Thus, we suggest that signaling strength, not activating mutations, can decide clinical outcome.

SAT513 Venous Thromboembolism and Thyroid Cancer. Analysis of National Inpatient Sample

Abstract Disclosure: M. Botros: None. N. Mazzaferro: None. P. Greenberg: None. D.A. Cohen: None. Introduction: Current literature describes the strong association between thrombosis risk and cancer. Multiple studies have shown a relationship between cancer and venous thromboembolism (VTE), a condition that occurs when a blood clot forms in a vein and includes deep vein thrombosis (DVT) and pulmonary embolism (PE) (1). Few European studies have shown an association between VTE and thyroid cancer (2). However, research studying the association of thyroid cancer with VTE in the United States or on a large scale is lacking. The discovery of thyroid cancer as a risk factor in the development of VTE may improve the detection of thyroid cancer and prevent future morbidity and mortality from thyroid cancer and VTE. Objectives: Using the National (Nationwide) Inpatient Sample (NIS) database, this study reports VTE incidence in various cancer types to determine if the association between VTE prevalence is higher in thyroid cancer than in other cancer types. The study also compared the coexistence of VTE and thyroid cancer in hospitalized patients to the prevalence in the general population. Methods: NIS uses ICD 9 and 10 diagnosis codes for extracting data. For this study, we obtained data for the years 2015-2017. In this analysis, we reviewed the number of patients over 18 admitted with ICD 10 codes with any of sixteen different cancer types and the diagnosis of VTE. We reviewed the literature comprehensively and selected sixteen types of cancer most commonly associated with VTE. Patients with coagulation disorders and pregnant patients with ICD-10-related codes were excluded. Other variables included smoking status, obesity, and gender. Results: Data from 3,471,240 hospitalized patients were collected. 1,662,710 (48%) were females. The cancers most commonly associated with VTE were lymphoid leukemia (22.3%), non-Hodgkin’s lymphoma (14.6 %), Hodgkin’s lymphoma (13%), pancreatic cancer (11.3%), and lung cancer (10%). The cancers with the lowest cancers VTE co-diagnosis were gall bladder (9.8%), urinary bladder (9%), stomach (9%), ovarian (8.7%), melanoma (7.7%), breast (7.2%), prostate (6.8%), uterine (6%), kidney (5.7%), colon (5.4%), and thyroid (3.3%). Conclusion: In this analysis, 3.3% of all patients with thyroid cancer carried a diagnosis of VTE. Although this suggests a relatively low risk, it is still higher than VTE incidence in the general population (0.001%) (3). The increased frequency of thyroid cancer in patients with VTE may warrant further screening for underlying thyroid cancer in patients with unprovoked PE. 1.Gervaso L, et al. Venous and Arterial Thromboembolism in Patients with Cancer. J Am Coll CardiolCardioOnc. 2021. 2.Walker AJ, et al. Incidence of venous thromboembolism in patients with cancer - A cohort study using linked United Kingdom databases. European Journal of Cancer. 3.Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001. Presentation Date: Saturday, June 17, 2023

The Relationship of Marital Status and The Implementation of Breast Self Examination on Women of Reliable Age

Breast Self Examination is carried out to reduce breast cancer mortality by finding breast cancer as early as possible and treating it when the size is still small before the cancer metastasizes. The discovery of breast cancer as early as possible that is diagnosed and treated correctly will increase the life expectancy of breast cancer sufferers. The purpose of this study was to determine the relationship between marital status and the implementation of Breast Self Examination in women of childbearing age. This research was a descriptive analytic study with cross sectional and carried out in the Working Area of BPM Hj. Rismawati, Maros Regency, South Sulawesi. The sample used 37 respondents, namely women of childbearing age with cluster sampling technique and tested using Fisher's exact test . The result of this study showed that there was a significant relationship between marital status and the implementation of the Breast Self Examination. In this study it was also concluded that marital status was not a risk factor for the implementation of the Breast Self Examination (OR value 0.47 < 1) or it can be said that unmarried women only had 0.47 times the risk of not doing Breast Self Examination compared to women who had married. It is needed to do further research on the respondents' perceptions, respondents' socio-cultural or community about breast cancer and early detection of breast cancer and respondents' insurance status